Cour RPC Sein 2016 - page 135

UBibliographie
1- Evan, Gerard I. 2006a. Can't kick that oncogene habit. Cancer Cell 10, n°
5 (Novembre): 345-347.2- Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R,
Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S,
Lindemann JP, Sapunar F, Martin M. 14TResults of the CONFIRM phase III trial
comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women
with estrogen receptor-positive advanced breast cancer.14T 13TJ Clin Oncol13T. 2010 Oct
20;28(30):4594-600.3- Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L,
Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F,
Lowe E, Piccart M.D14Touble-blind, randomized placebo controlled trial of fulvestrant
compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in
postmenopausal women with hormone receptor-positive, advanced breast cancer:
results from EFECT.13T14TJ Clin Oncol13T. 2008 Apr 1 ;26 (10):1664-70. 4- S.R. Johnston New strategies in estrogen receptor-positive breast cancer. Clin
Cancer Res, 16 (2010), pp. 1979–1987.5- J. Baselga, M. Campone, M. Piccart, et al. Everolimus in postmenopausal
hormone-receptor-positive advanced breast cancer. N Engl J Med, 366 (2012), pp.
520–529.6- Franke, T F. 2008. PI3K/Akt: getting it right matters. Oncogene 27, n°. 50
(Octobre 27): 6473-6488.7- Yuan, T L, et L C Cantley. 2008. PI3K pathway alterations in cancer:
variations on a theme. Oncogene 27, n°. 41 (Septembre 18): 5497-5510. 8- Sarbassov, D D, David A Guertin, Siraj M Ali, et David M Sabatini. 2005.
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science
(New York, N.Y.) 307, n°. 5712 (Février 18): 1098-1101. 9- Alessi, D R, M Andjelkovic, B Caudwell, P Cron, N Morrice, P Cohen, et B
A Hemmings. 1996. Mechanism of activation of protein kinase B by insulin and
IGF-1. The EMBO Journal 15, n°. 23 (Décembre 2) : 6541-6551.
15